Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis
about
Synergy and antagonism of combinations with quinolonesAntibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faeciumEvaluation of quinolones in experimental animal models of infections.Interaction between ciprofloxacin and rifampin.Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureusComparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Oral antibiotic therapy for the treatment of infective endocarditis: a systematic reviewIn vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin.Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditisTreatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureusCurrent perspectives on glycopeptide resistance.Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.In vivo antibiotic synergism: contribution of animal models.Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection modelInfluence of rifampin on fleroxacin pharmacokinetics.Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers.Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations.Rifampin combination therapy for nonmycobacterial infections.Rifampin for therapy of experimental pneumococcal meningitis in rabbits.Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection
P2860
Q28327424-A9797B05-3678-4D9E-9414-8DB0077707C9Q28378393-FA9980A9-D542-44BC-AA05-D19A7BA89994Q30446615-72B64879-0740-41FA-949B-D1078F4363CBQ33722507-78942E82-5EE5-44CF-BE29-04C4D8F7CA53Q33758399-3B165191-E5C8-43E1-8C0B-40A560F2B2B8Q33978084-6AD99342-2D21-449B-9FA4-771200B701C2Q33980069-B0AACF52-0D29-4DCC-82FE-22E5D42B951EQ34107094-F3853BA7-00BA-4C5F-AD2D-157CF1251198Q35116767-BE703F7D-F7A5-41FB-ABA3-FE86AF66A954Q35119494-84C444FC-7F51-4DF1-A32F-F32CBCB52A1EQ35121060-78D58A99-80BB-4F6F-B7E4-2432D45DDC5EQ35123155-1809FE2C-8954-4AAE-8FDC-D3EF71D93011Q35136601-66BE7F4E-C01B-49B3-BCB3-1A190A102D60Q35248574-80F20FB8-CEC0-4E30-A784-15C7DB764FA1Q35284471-B34149BE-B350-425A-9D21-FE3B3E082C46Q35368590-4001166F-F0BF-45B6-B591-E338F448341DQ35376362-A8CBE9A0-12BB-4F03-8FC9-E681978A3138Q35754023-F38B2A20-25F6-47F2-8979-B16523167FCFQ35822889-7D2309E2-B3D0-469F-B1C0-3E16B72A50A6Q35897356-9580AAC0-7176-4137-8745-E88DEF7442F6Q36757133-801EB6F3-AF6F-45D7-BBB3-ABF0BBA1F221Q36757553-221BB2B4-997D-4CF6-AC01-BECFE2034075Q37672039-E4DA61D8-EEC1-484A-8F68-45A79ECE0AB4Q39866960-606D66E0-2D79-492B-9CA7-C5B8D4A83CEFQ41913615-6A13BEA5-6F1D-432A-9279-89A105F06104
P2860
Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Ciprofloxacin and rifampin, al ...... hylococcus aureus endocarditis
@en
Ciprofloxacin and rifampin, al ...... ylococcus aureus endocarditis.
@nl
type
label
Ciprofloxacin and rifampin, al ...... hylococcus aureus endocarditis
@en
Ciprofloxacin and rifampin, al ...... ylococcus aureus endocarditis.
@nl
prefLabel
Ciprofloxacin and rifampin, al ...... hylococcus aureus endocarditis
@en
Ciprofloxacin and rifampin, al ...... ylococcus aureus endocarditis.
@nl
P2093
P2860
P356
P1476
Ciprofloxacin and rifampin, al ...... hylococcus aureus endocarditis
@en
P2093
P2860
P304
P356
10.1128/AAC.33.8.1184
P407
P577
1989-08-01T00:00:00Z